Review
doi: 10.1586/eri.10.63.
Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
Affiliations
- PMID: 20695746
- DOI: 10.1586/eri.10.63
Item in Clipboard
Review
Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies
Expert Rev Anti Infect Ther.
2010 Aug.
Abstract
The adverse impact of cytomegalovirus (CMV) infection after solid organ transplantion is currently believed to be mediated primarily by its immunomodulatory effects. There is a large body of evidence showing that both CMV disease and asymptomatic viremia are independent risk factors for the development of allograft rejection. The aim of this article is to summarize mechanisms whereby CMV is involved in the development and progression of allograft rejection, with particular emphasis on renal transplant recipients. The article will also address the potential of anti-CMV preventive protocols designed to favorably affect the incidence of allograft rejection.
Similar articles
-
Revisiting the effects of CMV on long-term transplant outcome.Curr Opin Organ Transplant. 2010 Aug;15(4):492-8. doi: 10.1097/MOT.0b013e32833bd3b5. Curr Opin Organ Transplant. 2010. PMID: 20631617 Review.
-
The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.J Clin Virol. 2006 Jun;36(2):146-51. doi: 10.1016/j.jcv.2006.01.015. Epub 2006 Mar 13. J Clin Virol. 2006. PMID: 16531113 Clinical Trial.
-
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.J Infect Dis. 2001 Dec 1;184(11):1461-4. doi: 10.1086/324516. Epub 2001 Oct 23. J Infect Dis. 2001. PMID: 11709790 Clinical Trial.
-
Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.Transplantation. 2009 Feb 15;87(3):436-44. doi: 10.1097/TP.0b013e318192ded5. Transplantation. 2009. PMID: 19202451
-
Benefits of cytomegalovirus prophylaxis in solid organ transplantation.Transplantation. 2006 Jul 27;82(2 Suppl):S4-8. doi: 10.1097/01.tp.0000230459.22968.26. Transplantation. 2006. PMID: 16858270 Review.
Cited by
-
Immunological Prediction of Cytomegalovirus (CMV) Replication Risk in Solid Organ Transplantation Recipients: Approaches for Regulating the Targeted Anti-CMV Prevention Strategies.Infect Chemother. 2017 Sep;49(3):161-175. doi: 10.3947/ic.2017.49.3.161. Infect Chemother. 2017. PMID: 29027383 Free PMC article. Review.
-
Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.J Am Soc Nephrol. 2012 Sep;23(9):1588-97. doi: 10.1681/ASN.2012010100. Epub 2012 Aug 23. J Am Soc Nephrol. 2012. PMID: 22917575 Free PMC article. Clinical Trial.
-
Current Knowledge on the Interaction of Human Cytomegalovirus Infection, Encoded miRNAs, and Acute Aortic Syndrome.Viruses. 2023 Sep 29;15(10):2027. doi: 10.3390/v15102027. Viruses. 2023. PMID: 37896804 Free PMC article. Review.
-
Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models.Front Immunol. 2023 Sep 6;14:1264496. doi: 10.3389/fimmu.2023.1264496. eCollection 2023. Front Immunol. 2023. PMID: 37744381 Free PMC article.
-
Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Clin J Am Soc Nephrol. 2015 Feb 6;10(2):294-304. doi: 10.2215/CJN.07020714. Epub 2014 Nov 25. Clin J Am Soc Nephrol. 2015. PMID: 25424991 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
